|
2006/OB/02
|
OXFORD BIOMEDICA ANNOUNCES BOARD APPOINTMENT
Oxford
BioMedica (LSE: OXB), the leading gene therapy company,
today announces that,
with immediate effect, Dr Mike McDonald has been promoted
to the Board as an executive director. He will maintain his
title of Chief Medical Officer. His primary responsibilities
include the Company’s clinical development activities
and regulatory affairs.
Mike has over 20 years of experience in clinical drug development and regulatory leadership. He joined Oxford BioMedica in September 2005 from Seattle Genetics, a US based biotechnology company, where he was Chief Medical Officer. Mike spent nine years with Eli Lilly serving as Worldwide Vice President, Clinical Research and Medical Affairs, and was previously at SmithKline Beecham for seven years where he was involved in worldwide clinical development, regulatory management and was a member of the pharmaceutical development strategy committee. From these positions Dr McDonald contributed to the successful registration and commercialisation of many important pharmaceuticals. He received his medical degree from Edinburgh University, he is a member of the Royal College of Physicians in London, holds a Diploma in Pharmaceutical Medicine and is a Fellow of the Faculty of Pharmaceutical Physicians.
Commenting on the Board appointment, Professor Alan Kingsman, Chief Executive of Oxford BioMedica, said: "Mike
has already made a significant and valuable contribution
to the Company since joining last year and has been instrumental
in the preparations for our planned Phase III trial of
TroVax in renal cell carcinoma. We are delighted to welcome
him to the Board."
There is no other information to be disclosed under Paragraph 9.6.13 R of the Listing Rules.
-
ends -
Return to the News
|
| Notes
| 1. |
Oxford
BioMedica |
|
Oxford BioMedica (LSE: OXB) is a biopharmaceutical company specialising in the development of novel gene-based therapeutics with a focus on the areas of oncology and neurotherapy. The Company was established in 1995 as a spin out from Oxford University, and is listed on the London Stock Exchange.
Oxford
BioMedica has core expertise in gene delivery,
as well as in-house clinical, regulatory
and manufacturing know-how. In oncology,
the pipeline includes an immunotherapy and
a gene therapy in multiple Phase II trials,
and a preclinical targeted antibody therapy
in collaboration with Wyeth. In neurotherapy,
the Company’s lead product is a gene
therapy for Parkinson’s disease, which
is expected to enter clinical trials in
2006, and four further preclinical candidates.
The Company is underpinned by over 80 patent
families, which represent one of the broadest
patent estates in the field.
The
Company has a staff of approximately
70 split between its main facilities
in Oxford and its wholly owned subsidiary,
BioMedica Inc, in San Diego, California.
Oxford BioMedica has corporate collaborations
with Wyeth, Intervet, Sigma-Aldrich,
Viragen, MolMed and Kiadis;
and has licensed technology to a number of
companies including Merck & Co, Biogen
Idec and Pfizer.
|
| |
| For
further information please contact:
|
|
|
Oxford BioMedica plc
Professor Alan
Kingsman, Chief Executive |
Tel: +44 (0)1865 783 000 |
| City/Financial
Enquiries
Lisa
Baderoon/Mark
Court/Mary-Jane Johnson
Buchanan Communications |
Tel: +44 (0)20 7466 5000 |
Scientific/Trade
Press Enquiries
Katja
Stout,Gemma
Bradley
College Hill - Life Sciences |
Tel:
+44 (0)20 7886 8150 |
|
|
|
|
|
Top
of page
Website by College Hill - Life Sciences |
| |
|
|
